A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
David Ivy, MD
Study ID
Protocol Number: 19-3001
More information available at ClinicalTrials.gov: NCT04175600
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers